Research programme: oral aminoglycosides - Galleon PharmaceuticalsAlternative Names: Amikacin oral - Galleon Pharmaceuticals; GALL 100; Oral aminoglycosides research programme - Galleon Pharmaceuticals
Latest Information Update: 06 Jan 2011
At a glance
- Originator Galleon Pharmaceuticals
- Mechanism of Action Protein 30S ribosomal subunit inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Gram-negative infections
Most Recent Events
- 22 Jun 2005 Preclinical trials in Gram-negative infections in USA (PO)